mda

Muscular Dystrophy Association Launches Nationwide Holiday Retail Campaign, Bringing Support for Families to Communities Across the Country

Annual campaign gives shoppers an opportunity to turn everyday purchases into meaningful impact for people living with muscular dystrophy, ALS and related neuromuscular diseases. NEW YORK – Wednesday, ...
Opinion
mdaOpinion

ACT for ALS Reauthorization Advances to the President After Today’s Senate Action

The Muscular Dystrophy Association applauds the United States Senate for passing the House’s version of the ACT for ALS (Accelerating Access to Critical Therapies for ALS) Reauthorization Act. With ...
mda

FDA Approves Isembyld (apitegromab-mstn), the First and Only Muscle-Targeted Therapy for Spinal Muscular Atrophy, Marking a New Milestone in SMA Treatment

New York, Friday, September 11, 2026 – The Muscular Dystrophy Association (MDA) marks another milestone for the neuromuscular community with the U.S. Food and Drug Administration (FDA) approval of ...
mda

Sleep and Breathing in Pediatric Neuromuscular Disorders (NMD)

A place where individuals and families are at the heart of everything we do.
mda

MDA Expands 2026 Engage Symposium Series, Bringing the Neuromuscular Community Together in Four U.S. Cities

Free, in-person events unite families, clinicians, researchers, and advocates to accelerate progress, advance care, and strengthen connection across the neuromuscular community. New York, Monday, June ...
mda

Muscular Dystrophy Association Announces $100,000 Investment to Advance LGMD Care at Leading MDA Care Centers with BridgeBio

New York, Tuesday, May 12, 2026 – The Muscular Dystrophy Association (MDA) today announced a $100,000 investment by BridgeBio to strengthen multidisciplinary care for people living with limb-girdle ...
mda

FDA Expands Approval of VYVGART and VYVGART Hytrulo to All Adults Living with Generalized Myasthenia Gravis

New York, Friday, May 8, 2026 – The Muscular Dystrophy Association (MDA) today welcomed the U.S. Food and Drug Administration’s (FDA) approval for label expansion of VYVGART® (efgartigimod alfa-fcab) ...
mda

Leading ALS Organizations Celebrate Introduction of ACT for ALS Reauthorization Act: Call for Swift Congressional Passage

Washington, D.C., April 8, 2026 – In support of this week’s introduction of the ACT for ALS Reauthorization Act of 2026 (H.R.8205), leading ALS advocacy organizations released the following statement ...
mda

Muscular Dystrophy Association Marks Rare Disease Day by Spotlighting Community Stories Driving Progress in Research, Care, and Advocacy

New York, Monday, January 26, 2026 – In recognition of Rare Disease Day on February 28, the Muscular Dystrophy Association (MDA) is sharing powerful community stories throughout the month that reflect ...
mda

MDA Announces 2026 National Ambassador Lily Sander Following Landmark Years of National Advocacy

Lily Sander will commence her second year as MDA National Ambassador by speaking at the largest global gathering of the neuromuscular community on March 9 at the 2026 MDA Clinical & Scientific ...
mda

Applications Now Open for MDA’s 2026 Summer Camp Season

As Muscular Dystrophy Association looks ahead to its next 75 years, the 71st MDA Summer Camp session continues a legacy of empowering the next generation of youth living with neuromuscular conditions.